Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 2Phase 1 2

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Breast 1

Conditions

Salivary Gland Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Breast Neoplasms 1

Interventions

Specimen Handling 128Magnetic Resonance Spectroscopy 105Biopsy 76pembrolizumab 63Nivolumab 60Carboplatin 59Cisplatin 57Cyclophosphamide 53Paclitaxel 44Radiotherapy 36Bevacizumab 36Gemcitabine 34Dexamethasone 33Rituximab 26Doxorubicin 26olaparib 25Pemetrexed 25Fluorouracil 25atezolizumab 24Radiation 24Injections 23Docetaxel 23fludarabine 22durvalumab 22Vincristine 21Prednisone 21Oxaliplatin 21Ipilimumab 21Cytarabine 21venetoclax 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Gonadotropin-Releasing Hormone × 30 days × Clear all
NCT04325828 2026-06-05

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

NCT07610733 2026-05-28

IFOCOS

Fudan University

Phase 2 Not yet recruiting
100 enrolled
Breast

Breast Neoplasms

NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡